Tulisokibart, a monoclonal antibody targeting tumor necrosis factor–like cytokine 1A (TL1A), yielded significant and clinically meaningful differences from placebo in ulcerative colitis clinical remission during a recent phase 2 trial.
The trial evaluated tulisokibart, in development by Prometheus (Merck), in patients who were dependent on glucocorticoids or failed conventional therapies (N Engl J Med 2024; 391[12]:1119-1129). Investigators randomized patients to receive intravenous